[(4-氟苯基)肼基]氯乙酸乙酯 | 37522-19-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: [(4-氟苯基)肼基]氯乙酸乙酯
• 中文别名: 2-氯-2-[2-(4-氟苯基)肼基]乙酸乙酯
• 英文名称: 2-Chlor-2-(4-fluorphenylhydrazono)-essigsaeure-ethylester
• 英文别名: ethyl (Z)-2-chloro-2-(2-(4-fluorophenyl)hydrazono)acetate；ethyl chloro[(4-fluorophenyl)hydrazono]acetate；ethyl (2Z)-2-chloro-2-[(4-fluorophenyl)hydrazinylidene]acetate
• CAS: 37522-19-3
• 化学式: C₁₀H₁₀ClFN₂O₂
• 分子量: 244.653
• InChiKey: VVERUMZUZIFIQN-ZROIWOOFSA-N

物化性质

• 熔点：
  109 °C(Solv: ethanol (64-17-5))
• 沸点：
  307.3±44.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2928000090

反应信息

• 作为反应物：
  描述：

  [(4-氟苯基)肼基]氯乙酸乙酯 在 三氟乙酸 、 三甲胺 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 7.0h， 生成 ethyl 1-(4-fluorophenyl)-6-(4-nitrophenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element

  摘要：

  Four series of novel and potent FXa inhibitors possessing the 1,2,4-triazole moiety and pyrrole moiety as P2 binding element and dihydroimidazoleitetrahydropyrimidine groups as P4 binding element were designed, synthesized, and evaluated for their anticoagulant activity in human and rabbit plasma in vitro. Most compounds showed moderate to excellent activity. Compounds 14a, 16, 18c, 26c, 35a, and 35b were further examined for their inhibition activity against human FXa in vitro and rat venous thrombosis in vivo. The most promising compound 14a, with an IC50 (FXa) value of 0.15 mu M and 99% inhibition rate, was identified for further evaluation as an FXa inhibitor. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.09.024
• 作为产物：
  描述：

  4-氟苯胺 、 2-氯乙酰乙酸乙酯 在 盐酸 、 sodium nitrite 、 sodium acetate 作用下， 以 水 为溶剂， 反应 2.0h， 以83.3%的产率得到[(4-氟苯基)肼基]氯乙酸乙酯
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element

  摘要：

  Four series of novel and potent FXa inhibitors possessing the 1,2,4-triazole moiety and pyrrole moiety as P2 binding element and dihydroimidazoleitetrahydropyrimidine groups as P4 binding element were designed, synthesized, and evaluated for their anticoagulant activity in human and rabbit plasma in vitro. Most compounds showed moderate to excellent activity. Compounds 14a, 16, 18c, 26c, 35a, and 35b were further examined for their inhibition activity against human FXa in vitro and rat venous thrombosis in vivo. The most promising compound 14a, with an IC50 (FXa) value of 0.15 mu M and 99% inhibition rate, was identified for further evaluation as an FXa inhibitor. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.09.024

文献信息

• Regiospecific Synthesis of Novel 6-Amino-5-hydroxypyridazin-3(2<i>H</i>)-ones
  作者：Peter Dragovich、Julie Blazel、Kimkim Dao、David Ellis、Lian-Sheng Li、Douglas Murphy、Frank Ruebsam、Chinh Tran、Yuefen Zhou

  DOI：10.1055/s-2008-1032157

  日期：2008.2

  The synthesis of a novel class of 6-amino-5-hydroxy-pyridazin-3(2 H)-ones (3-oxo-2,3-dihydropyridazines) is described. These compounds also contain an ethoxycarbonyl moiety at the 4-position of the pyridazinone ring. They are prepared in good to moderate yields (30-72%) by the condensation of disubstituted amines with (alkylhydrazono)- or (arylhydrazono)(chloro)acetates followed by subsequent acylation

  描述了一类新型 6-amino-5-hydroxy-pyridazin-3(2 H)-ones (3-oxo-2,3-dihydropyridazines) 的合成。这些化合物还在哒嗪酮环的 4 位含有乙氧羰基部分。它们通过二取代胺与（烷基肼基）或（芳基肼基）（氯）乙酸酯的缩合，然后用乙基丙二酰氯和 Dieckmann 环化，以良好至中等的产率（30-72%）制备。描述了对新方法的范围和局限性的初步评估，以及哒嗪酮制剂中使用的几种（烷基肼基）（氯）乙酸酯底物的新合成。
• Nichtsteroidale Entzündungshemmer, 11. Mitt.1) Antiphlogistische Pyrazolderivate, III
  作者：Helmut Biere、Irmgard Böttcher、Joachim-Friedrich Kapp

  DOI：10.1002/ardp.19833160706

  日期：——

  Ergänzend zu kürzlich beschriebenen Pyrazol‐Derivaten1,2) wurden neue Strukturvarianten der klinischen Prüfverbindung 1f (Pirazolac) mit verändertem Substitutionsmuster in den Positionen 4 und 5 am Pyrazolring synthetisiert. Die in Entzündungsmodellen (Ratte) erhaltenen Testresultate werden diskutiert und die Struktur‐Aktivitätsbeziehung erörtert.

  除了最近描述的吡唑衍生物 1,2)，还合成了临床试验化合物 1f（吡唑酸）的新结构变体，在吡唑环上的 4 和 5 位具有修饰的取代模式。讨论了在炎症模型（大鼠）中获得的测试结果并讨论了构效关系。
• Process for the preparation of (1,4-diaryl-pyrazol-3-yl)-acetic acids
  申请人：SEUREF A.G.

  公开号：EP0349919A2

  公开（公告）日：1990-01-10

  (1,4-diaryl-pyrazol-3-yl)-acetic acids of the formula I wherein Ar and Ar′, which can be the same or differen, represen a phenyl group optionally substituted with 1 to 3 halogen atoms, C₁-C₄ alkyl or C₁-C₄ alkoxy groups, are prepared by reacting β-styryl amines with compounds of formula ClCO-CH₂-A (wherein A represent a CN, COOR or CONR¹R² group, R being an alkyl, benzyl or benzohydryl group and R¹and R² being H or an alkyl, benzyl or benzohydryl group).

  式 I 的(1,4-二芳基吡唑-3-基)乙酸 其中 Ar 和 Ar′（可以相同或不同）代表任选被 1 至 3 个卤素原子、C₁-C₄ 烷基或 C₁-C₄烷氧基取代的苯基、将 β-苯乙烯胺与式 ClCO-CH₂-A 的化合物（其中 A 代表 CN、COOR 或 CONR¹R²，R 为烷基、苄基或苯甲酰基，R¹和 R² 为 H 或烷基、苄基或苯甲酰基）反应制备。
• PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF
  申请人：Chengdu Easton Biopharmaceuticals Co., Ltd.

  公开号：EP3072892A1

  公开（公告）日：2016-09-28

  The present invention relates to the field of pharmaceutical chemistry, specifically to a class of compounds containing lactam and derivative thereof, and especially to a pyridine derivative as shown in general formula (I), preparation method and the use thereof as a Factor Xa inhibitor. The present invention further relates to the medical use of the compound and derivative thereof in preparation of anticoagulant drugs, particularly to the use in preparation of drugs for preventing or treating thrombosis or embolism.

  本发明涉及药物化学领域，具体涉及一类含内酰胺的化合物及其衍生物，尤其涉及通式（I）所示的吡啶衍生物、制备方法及其作为Xa因子抑制剂的用途。本发明进一步涉及该化合物及其衍生物在制备抗凝药物中的医疗用途，特别是在制备预防或治疗血栓或栓塞药物中的用途。
• [EN] PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF<br/>[FR] DÉRIVÉ PYRIDINE ET SON UTILISATION MÉDICALE<br/>[ZH] 一种吡啶类衍生物及其医药用途
  申请人：CHENGDU EASTON PHARMACEUTICAL

  公开号：WO2015070809A1

  公开（公告）日：2015-05-21

  本发明涉及药物化学领域，具体涉及一类含有内酰胺的化合物及其衍生物，特别是涉及一种如通式（I）所示吡啶类衍生物、其制备方法及其作为Xa因子抑制剂的用途。本发明进一步涉及上述化合物及其衍生物在制备抗凝药物中的医药用途，特别是在制备预防或治疗血栓形成或栓塞药物中的用途。